Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XenoPort has reported revenues of $389,000 for the third quarter ended 30 September 2010, compared to $403,000 for the same period in 2009.
Subscribe to our email newsletter
XenoPort has posted a net loss of $19.9m for the third quarter 2010, or $0.65 loss per diluted share, compared to a net loss of $24.37m, or $0.81 loss per diluted share, for the comparable period in 2009.
For the nine months ended 30 September 2010 revenue was $973,000, compared to $28.51m for the year ago period.
For the nine months ended 30 September 2010, XenoPort posted a net loss of $67.65m, or $2.22 loss per diluted share, compared to $47.99m, or $1.7 loss per diluted share, for the year ago period.
XenoPort CEO Ronald Barrett said that the company has made significant progress in advancing the product candidates in the last quarter.
"With respect to Horizant, we worked closely with GSK on the NDA resubmission and are pleased that the FDA has accepted it for review and set an April 6, 2011 PDUFA date," Barrett said.
"We have also been working with Astellas to address questions raised by the Pharmaceuticals and Medical Device Agency (PMDA) as they review the NDA for XP13512 as a potential treatment of restless legs syndrome in Japan."